NIKI.US Niki BioSolutions, Inc.
- Market cap
- USD 5.15M
- P/E
- -
- P/B
- 0.06x
- ROE
- -5.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is NIKI.US undervalued?
Graham numberThe Graham number of Niki BioSolutions, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Niki BioSolutions, Inc. fundamental analysis
No fundamental analysis for Niki BioSolutions, Inc. yet.
Niki BioSolutions, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Niki BioSolutions, Inc.
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment…
Full company profileNiki BioSolutions, Inc. financial statements
Niki BioSolutions, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | 383K | 535K | 912K | 1.54M | 1.30M | 431K | 0.00 | 0.00 |
| Gross Profit | -58.9K | 65.4K | -259K | -104K | 81.9K | 80.1K | 10.6K | -255K | 0.00 |
| Operating Income | -5.69M | -10.3M | -18.2M | -19.9M | -19.2M | -17.5M | -10.6M | -3.80M | -1.82M |
| EBITDA | -2.50M | -9.99M | -15.1M | 6.50M | -25.8M | -9.97M | -9.22M | -3.71M | -1.82M |
| Net Income | -2.55M | -14.8M | -18.7M | 7.07M | -25.0M | -9.80M | -2.83M | -4.27M | -1.36M |
| EPS | -85 | -531 | -644 | 224 | -715 | -275 | -62 | -78 | -19 |
| Balance Sheet | |||||||||
| Total Assets | 31.6M | 45.1M | 24.0M | 44.2M | 21.9M | 20.9M | 20.6M | 16.1M | 18.7M |
| Total Liabilities | 1.33M | 12.3M | 9.10M | 6.08M | 4.40M | 13.0M | 5.26M | 4.35M | 4.90M |
| Shareholders' Equity | 30.2M | 33.1M | 16.4M | 41.8M | 23.6M | 15.7M | 24.8M | 21.1M | 23.2M |
| Cash & Short-term Investments | 18.2M | 13.0M | 6.25M | 31.9M | 8.50M | 1.99M | 2.01M | 874K | 3.45M |
| Total Debt | 480K | 10.3M | 6.47M | 3.32M | 217K | 6.85M | 3.28M | 3.35M | 3.44M |
| Cash Flow | |||||||||
| Operating Cash Flow | -5.78M | -10.0M | -13.4M | -15.9M | -14.7M | -12.3M | -7.72M | -1.19M | -1.84M |
| Capital Expenditure | 3.06M | 6.06M | 1.11M | 161K | 138K | 187K | 3.02K | 0.00 | 0.00 |
| Free Cash Flow | -8.84M | -16.1M | -14.5M | -16.1M | -14.8M | -12.5M | -7.73M | -1.19M | -1.84M |
| Ratios | |||||||||
| ROE | -8.4% | -44.8% | -114.2% | 16.9% | -106.1% | -62.4% | -11.4% | -20.2% | -5.9% |
| ROA | -8.1% | -32.9% | -78.0% | 16.0% | -114.3% | -47.0% | -13.7% | -26.5% | -7.3% |
| Net Profit Margin | - | -3,868.0% | -3,491.8% | 775.3% | -1,624.4% | -756.2% | -654.9% | - | - |
| Debt to Equity | 0.02x | 0.31x | 0.40x | 0.08x | 0.01x | 0.44x | 0.13x | 0.16x | 0.15x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Niki BioSolutions, Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 756K | 24 | 10.7% |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Jul 20, 2026.
Who owns Niki BioSolutions, Inc.
- Insiders 47.53%
- Institutions 0.56%
- Public & others 51.92%
- Shares outstanding 2.94M
- Free float 536K
Top institutions holding NIKI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Citadel Advisors Llc | 24.5K | 0.08% | -73.50% | Jun 2026 |
| Advisor Group Holdings, Inc. | 5.50K | 0.02% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 7.00 | 0.00% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Susquehanna International Group, LLP | 0.00 | 0.00% | -100.00% | Jun 2026 |
| XTX Topco Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
Niki BioSolutions, Inc. company profile
- Company name
- Niki BioSolutions, Inc.
- Ticker
- NIKI.US
- Exchange
- USA Stocks
- Listed since
- Jul 17, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- December
- Address
- 116 Village Boulevard, Princeton, NJ, United States, 08540
- Phone
- 609 951 2222
- Website
- aptorumgroup.com
About Niki BioSolutions, Inc.
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule, which is in a preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as Aptorum Group Limited and changed its name to Niki BioSolutions, Inc. in July 2026. Niki BioSolutions, Inc. was incorporated in 2010 and is headquartered in Princeton, New Jersey. Niki BioSolutions, Inc. operates as a subsidiary of Jurchen Investment Corporation.
Niki BioSolutions, Inc. management
4- Mr. Chung Yuen HuenFounder, Executive Chairman & CEO · born 1980
- Mr. Kwok Kuen WongHead of Finance · born 1956
- Dr. Alidad Mireskandari M.B.A., Ph.D.President, COO & Board Observer · born 1968
- Mr. Thomas John Freeburg Ph.D.Chief Financial Officer · born 1968